ReviewClinical and translational radiation oncology2026
Primary adrenal insufficiency in patients with bilateral adrenal metastases treated with curative ablative radiation therapy: A comprehensive review of literature and expert agreements for radiation practice.
Review in Clinical and translational radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Bilateral adrenal metastases are rare but clinically significant. While stereotactic body radiotherapy (SBRT) provides excellent local control, the risk of post-treatment primary adrenal insufficiency (PAI) after bilateral irradiation remains poorly defined and lacks standardized management guidelines. Methods: We performed a comprehensive literature review following PRISMA principles, using PubMed and Embase databases (January 1956 to June 2025). Studies including patients with bilateral adrenal metastases treated with radiotherapy, or unilateral irradiation in the setting of a solitary adrenal gland, were eligible. Data on treatment characteristics, incidence of PAI, diagnostic approaches, and management were extracted. In parallel, a multidisciplinary expert panel developed expert opinion-based practical recommendations for the screening, treatment, and follow-up of PAI. Results: Thirty studies comprising 156 patients treated with bilateral adrenal irradiation (or irradiation of a solitary adrenal gland) were included. PAI was reported in 47 patients (30%), although systematic endocrine evaluation was performed in only a minority of studies, suggesting potential underestimation. Time to onset ranged from 3 to 30 months. Reporting of diagnostic work-up, management, and follow-up was highly heterogeneous, and treatment details were frequently lacking. No study identified reliable dosimetric predictors of PAI, and no association between radiation dose parameters and adrenal insufficiency was demonstrated. Conclusions: PAI following bilateral adrenal radiotherapy is likely under-recognized and under-reported, with clinically meaningful incidence and potential life-threatening consequences. In the absence of robust data, systematic hormonal assessment, careful treatment planning, and structured long-term follow-up are essential. We propose practical, expert-based recommendations to guide clinical management, while emphasizing the need for prospective studies to better define incidence, risk factors, and optimal prevention strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.